Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This systematic review evaluated the safety of JAK-inhibitors for alopecia areata, finding that most adverse events were mild and systemic formulations were well-tolerated; however, increased rates of certain infections and laboratory abnormalities were noted, with isolated severe cases but no fatal outcomes.

This article discusses the need for changes in governance and regulation within the aesthetics industry, focusing on creating standards and competency frameworks to ensure safe practices. Results are not reported in this summary.

JAK inhibitors are generally safe for treating alopecia areata.

This study found that among various JAK inhibitors for severe alopecia areata, baricitinib_4 mg demonstrated significant efficacy with high precision, while deuruxolitinib_12 mg showed the best efficacy but with wider confidence intervals, providing clinicians valuable information for treatment selection.

JAK inhibitors may reduce depression risk in alopecia areata patients.

Infections and missed treatments trigger flares in alopecia areata patients on JAK inhibitors.

This study suggests recommendations for treating and referring patients with severe complications from dermal filler injections, highlighting the need for careful treatment to avoid scarring.

This study conducted a survey among consultant dermatologists in Ireland to explore their use of JAK inhibitors for treating alopecia areata, acknowledging challenges posed by the lack of global guidelines and long-term safety data.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

This article discusses Janus kinase inhibitors as a promising future treatment for alopecia areata but does not present new research findings.

In this study, JAUN soap was found to improve skin conditions, such as moisture, elasticity, and cleansing effectiveness, without adverse reactions, suggesting its potential as a safe and effective ingredient for functional cosmetics.

This article provides an overview of the 19th Annual Dermatology Update, but reports no new clinical findings.

Switching Janus kinase inhibitors helped some patients with severe alopecia areata regrow hair, but insurance issues can worsen the condition.

This study found that oral JAK inhibitors significantly improve hair regrowth in adults with moderate-to-severe alopecia areata compared to placebo, although they are associated with a higher risk of non-serious adverse events.

This abstract discusses the 2021 virtual Dermatology Nurses' Association Convention, outlining key dermatological insights shared, but it presents no new research findings or clinical results.

In this randomized, placebo-controlled trial, adults with severe chronic alopecia areata who received deuruxolitinib showed significant hair regrowth compared to placebo over 24 weeks, and the treatment was generally well-tolerated, though long-term effects remain unexamined.

This study identified two novel mutations in the CDH3 gene causing HJMD in a Chinese patient, expanding the genetic and phenotypic understanding of the disorder.

Dermatologists are hesitant to prescribe Janus kinase inhibitors for alopecia areata due to safety concerns and lack of knowledge.

Deuruxolitinib effectively promotes hair regrowth in alopecia areata.

This study reports that the newly developed SA-Ca(II) hydrogel has tunable mechanical properties, high biocompatibility, and potential applications in wearable protections and stimuli-responsive electronics.

This study suggests that although data on JAK inhibitors for treating LPP and FFA is mainly from retrospective studies and case reports, these inhibitors may offer a new treatment option, particularly for challenging cases.

This study found that Janus kinase inhibitors significantly improve treatment outcomes for complex skin conditions like atopic dermatitis and alopecia areata, but their implementation requires careful safety considerations, including risk assessments for cardiovascular, malignant, and reproductive issues.

In this case report, two female patients with refractory systemic lupus erythematosus showed significant improvement after treatment with the JAK inhibitor upadacitinib, indicating potential as a promising option for difficult cases, although further research is needed to confirm its broader safety and efficacy.

This case study reports that a heterozygous missense GJA1 mutation, p.Gly138Ser, in a 2-year-old boy with oculodentodigital syndrome primarily resulted in syndactyly, fifth finger hypoplasia, and hypotrichosis, without neurological or craniofacial abnormalities.

This case study reported significant hair regrowth in a young female patient with alopecia areata after 60 days of Ayurvedic treatment, including leech therapy and herbal medicines, demonstrating its potential effectiveness according to the authors' observations.

This study found that a dopamine-methacrylated hyaluronic acid hydrogel enhances the efficacy of adipose-derived stem cells in promoting skin regeneration, potentially involving the Notch signaling pathway.